Wealth Effects LLC Has $101,000 Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Wealth Effects LLC lowered its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 16.1% in the 4th quarter, HoldingsChannel reports. The firm owned 42,800 shares of the company’s stock after selling 8,200 shares during the period. Wealth Effects LLC’s holdings in Autolus Therapeutics were worth $101,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in AUTL. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the second quarter valued at about $43,000. Millennium Management LLC increased its position in Autolus Therapeutics by 113.7% in the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after buying an additional 432,503 shares in the last quarter. Herbst Group LLC acquired a new position in Autolus Therapeutics during the 3rd quarter worth approximately $91,000. Exchange Traded Concepts LLC raised its stake in Autolus Therapeutics by 9.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after buying an additional 3,740 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AUTL has been the topic of a number of research reports. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Trading Down 2.7 %

NASDAQ AUTL opened at $2.20 on Wednesday. The business has a fifty day simple moving average of $2.57 and a 200 day simple moving average of $3.48. Autolus Therapeutics plc has a 12 month low of $2.07 and a 12 month high of $7.37. The firm has a market capitalization of $585.40 million, a P/E ratio of -1.82 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) EPS. As a group, sell-side analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.